Literature DB >> 26888894

Increased Remnant Cholesterol Explains Part of Residual Risk of All-Cause Mortality in 5414 Patients with Ischemic Heart Disease.

Anne-Marie K Jepsen1, Anne Langsted1, Anette Varbo1, Lia E Bang2, Pia R Kamstrup1, Børge G Nordestgaard3.   

Abstract

BACKGROUND: Increased concentrations of remnant cholesterol are causally associated with increased risk of ischemic heart disease. We tested the hypothesis that increased remnant cholesterol is a risk factor for all-cause mortality in patients with ischemic heart disease.
METHODS: We included 5414 Danish patients diagnosed with ischemic heart disease. Patients on statins were not excluded. Calculated remnant cholesterol was nonfasting total cholesterol minus LDL and HDL cholesterol. During 35836 person-years of follow-up, 1319 patients died.
RESULTS: We examined both calculated and directly measured remnant cholesterol; importantly, however, measured remnant cholesterol made up only 9% of calculated remnant cholesterol at nonfasting triglyceride concentrations <1 mmol/L (89 mg/dL) and only 43% at triglycerides >5 mmol/L (443 mg/dL). Multivariable-adjusted hazard ratios for all-cause mortality compared with patients with calculated remnant cholesterol concentrations in the 0 to 60th percentiles were 1.2 (95% CI, 1.1-1.4) for patients in the 61st to 80th percentiles, 1.3 (1.1-1.5) for the 81st to 90th percentiles, 1.5 (1.1-1.8) for the 91st to 95th percentiles, and 1.6 (1.2-2.0) for patients in the 96th to 100th percentiles (trend, P < 0.001). Corresponding values for measured remnant cholesterol were 1.0 (0.8-1.1), 1.2 (1.0-1.4), 1.1 (0.9-1.5), and 1.3 (1.1-1.7) (trend, P = 0.006), and for measured LDL cholesterol 1.0 (0.9-1.1), 1.0 (0.8-1.2), 1.0 (0.8-1.3), and 1.1 (0.8-1.4) (trend, P = 0.88). Cumulative survival was reduced in patients with calculated remnant cholesterol ≥1 mmol/L (39 mg/dL) vs <1 mmol/L [log-rank, P = 9 × 10(-6); hazard ratio 1.3 (1.2-1.5)], but not in patients with measured LDL cholesterol ≥3 mmol/L (116 mg/dL) vs <3 mmol/L [P = 0.76; hazard ratio 1.0 (0.9-1.1)].
CONCLUSIONS: Increased concentrations of both calculated and measured remnant cholesterol were associated with increased all-cause mortality in patients with ischemic heart disease, which was not the case for increased concentrations of measured LDL cholesterol. This suggests that increased concentrations of remnant cholesterol explain part of the residual risk of all-cause mortality in patients with ischemic heart disease.
© 2016 American Association for Clinical Chemistry.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26888894     DOI: 10.1373/clinchem.2015.253757

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  28 in total

Review 1.  Apolipoprotein E and Atherosclerosis.

Authors:  A D Marais
Journal:  Curr Atheroscler Rep       Date:  2021-05-10       Impact factor: 5.113

2.  Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.

Authors:  Makoto Kinoshita; Koutaro Yokote; Hidenori Arai; Mami Iida; Yasushi Ishigaki; Shun Ishibashi; Seiji Umemoto; Genshi Egusa; Hirotoshi Ohmura; Tomonori Okamura; Shinji Kihara; Shinji Koba; Isao Saito; Tetsuo Shoji; Hiroyuki Daida; Kazuhisa Tsukamoto; Juno Deguchi; Seitaro Dohi; Kazushige Dobashi; Hirotoshi Hamaguchi; Masumi Hara; Takafumi Hiro; Sadatoshi Biro; Yoshio Fujioka; Chizuko Maruyama; Yoshihiro Miyamoto; Yoshitaka Murakami; Masayuki Yokode; Hiroshi Yoshida; Hiromi Rakugi; Akihiko Wakatsuki; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2018-08-22       Impact factor: 4.928

3.  Multidimensional regulation of lipoprotein lipase: impact on biochemical and cardiovascular phenotypes.

Authors:  Robert A Hegele
Journal:  J Lipid Res       Date:  2016-07-13       Impact factor: 5.922

4.  Prognostic utility of triglyceride-rich lipoprotein-related markers in patients with coronary artery disease.

Authors:  Ye-Xuan Cao; Hui-Wen Zhang; Jing-Lu Jin; Hui-Hui Liu; Yan Zhang; Rui-Xia Xu; Ying Gao; Yuan-Lin Guo; Cheng-Gang Zhu; Qi Hua; Yan-Fang Li; Raul D Santos; Na-Qiong Wu; Jian-Jun Li
Journal:  J Lipid Res       Date:  2020-07-08       Impact factor: 5.922

Review 5.  The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk.

Authors:  Pratik B Sandesara; Salim S Virani; Sergio Fazio; Michael D Shapiro
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

6.  Upregulation of Circulating Cardiomyocyte-Enriched miR-1 and miR-133 Associate with the Risk of Coronary Artery Disease in Type 2 Diabetes Patients and Serve as Potential Biomarkers.

Authors:  Haifa Abdulla Al-Muhtaresh; Abdel Halim Salem; Ghada Al-Kafaji
Journal:  J Cardiovasc Transl Res       Date:  2019-01-04       Impact factor: 4.132

Review 7.  Which Lipids Should Be Analyzed for Diagnostic Workup and Follow-up of Patients with Hyperlipidemias?

Authors:  Michel R Langlois; Børge G Nordestgaard
Journal:  Curr Cardiol Rep       Date:  2018-08-17       Impact factor: 2.931

Review 8.  Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.

Authors:  Paul D Rosenblit
Journal:  Curr Diab Rep       Date:  2019-11-21       Impact factor: 4.810

Review 9.  Advances in lipid-lowering therapy through gene-silencing technologies.

Authors:  Børge G Nordestgaard; Stephen J Nicholls; Anne Langsted; Kausik K Ray; Anne Tybjærg-Hansen
Journal:  Nat Rev Cardiol       Date:  2018-02-08       Impact factor: 32.419

10.  Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study.

Authors:  Julian C van Capelleveen; Sang-Rok Lee; Rutger Verbeek; John J P Kastelein; Nicholas J Wareham; Erik S G Stroes; G Kees Hovingh; Kay-Tee Khaw; S Matthijs Boekholdt; Joseph L Witztum; Sotirios Tsimikas
Journal:  J Clin Lipidol       Date:  2018-08-29       Impact factor: 4.766

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.